Skip to content
10-Q

Quarterly Report

Iterum Therapeutics plc ITRMF

0000950170-25-069802

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 40M sh
Shares Diluted Q1 2025 · Mar 31, 2025 34.06M sh
Shares Diluted Q1 2025 · Mar 31, 2024 15.43M sh
Capex Q1 2025 · Mar 31, 2025 $2K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$3.06M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$13.08M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $12.65M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $24.13M
Stockholders Equity Q1 2025 · Mar 31, 2025 −$2.55M
Stockholders Equity Q1 2025 · Dec 31, 2024 −$4.08M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$6.15M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$6.4M
Current Liabilities Q1 2025 · Mar 31, 2025 $3.63M
Current Liabilities Q1 2025 · Dec 31, 2024 $17.61M
Total Liabilities Q1 2025 · Mar 31, 2025 $35.53M
Total Liabilities Q1 2025 · Dec 31, 2024 $48.68M
Current Assets Q1 2025 · Mar 31, 2025 $13.51M
Current Assets Q1 2025 · Dec 31, 2024 $24.79M
Total Assets Q1 2025 · Mar 31, 2025 $32.98M
Total Assets Q1 2025 · Dec 31, 2024 $44.6M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.14
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.46
Eps Basic Q1 2025 · Mar 31, 2025 −$0.14
Eps Basic Q1 2025 · Mar 31, 2024 −$0.46
Rd Expense Q1 2025 · Mar 31, 2025 $591K
Rd Expense Q1 2025 · Mar 31, 2024 $3.98M
Net Income Q1 2025 · Mar 31, 2025 −$4.89M
Net Income Q1 2025 · Dec 31, 2024 −$24.77M
Net Income Q1 2025 · Mar 31, 2024 −$7.1M
Operating Income Q1 2025 · Mar 31, 2025 −$3.71M
Operating Income Q1 2025 · Mar 31, 2024 −$6.16M